Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

Authors

Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
Kowser Miah (ORCID: https://orcid.org/0009-0003-4319-6728)
David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
Ganesh Mugundu (ORCID: https://orcid.org/0000-0002-3736-1884)
Judy S. Wang (ORCID: https://orcid.org/0000-0003-4789-4913)
Gerald S. Falchook (ORCID: https://orcid.org/0000-0001-9165-2191)
Esteban Rodrigo Imedio (ORCID: https://orcid.org/0000-0001-5666-666X)
Suzanne F. Jones (ORCID: https://orcid.org/0000-0001-6881-8050)
Sanjeev Kumar (ORCID: https://orcid.org/0000-0003-3847-671X)

Institutions

AstraZeneca (United Kingdom) (GB)
Sarah Cannon (US)
Florida Cancer Specialists & Research Institute (US)
HealthONE (US)
AstraZeneca (United States) (US)

Publication Details

Journal: Targeted Oncology
Published: 2024-11-19
DOI: https://doi.org/10.1007/s11523-024-01110-8
Citations: 6
Primary Topic: Peptidase Inhibition and Analysis
Type: article
Field-Weighted Citation Impact: 1.70

Funders

AstraZeneca

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

Erika Hamilton, Manish R. Patel, Kowser Miah, David R. Spigel et al.

Nov 19, 2024

6 citations

Targeted Oncology

Peptidase Inhibition and Analysis

1.70

article

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

Erika Hamilton, Manish R. Patel, Kowser Miah, David R. Spigel, Ganesh Mugundu, Judy S. Wang, Gerald S. Falchook, Esteban Rodrigo Imedio, Suzanne F. Jones, Sanjeev Kumar

November 19, 2024article en

6 citations

Abstract

No abstract available for this paper.

Targeted OncologyVol. 20(1)

AstraZeneca (United Kingdom) (GB), Sarah Cannon (US), Florida Cancer Specialists & Research Institute (US), HealthONE (US), AstraZeneca (United States) (US)

AstraZeneca

Good health and well-being

Openalex Percentile: Top 13%

Peptidase Inhibition and Analysis

1.70

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors — Erika Hamilton, Manish R. Patel, et al. · Targeted Oncology (2024) | TGRS Research Map | TGRS